GameChangers: Negotiating High-Cost Drugs

This episode discusses the 2023 Inflation Reduction Act and HHS’s authority to negotiate prices for high-cost drugs in Medicare Part D. In addition to the initial list of 10 drugs, HHS is now focused on medications used in the hospital and covered under Medicare Part B.

THE GAMECHANGER: HHS updates the Inflation Reduction Act that will impact over 750, 000 people.

Upon successful completion of this course, learners should be able to:
1. Describe the monetary impact of the Inflation Reduction Act.
2. Discuss how the Medicare Part B drug addition will benefit patients.

Jake Galdo, PharmD, MBA, BCPS, BCGP
CEO
Seguridad

Dr. Galdo disclosed that his spouse is an employee at Eli Lilly. All relevant financial relationships have been mitigated.

Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: April 8, 2024
Planned Expiration Date: April 8, 2025

Universal Activity Number (UAN): 0107-0000-24-136-H04-P

Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information

Duration	0h 30m
Topic Designator	Operations
ACPE	Yes
ACPE Topic	04 Pharmacy Administration
Role	Pharmacist
Media-Type	Podcast
Release Date	4/8/24
CEUs	0.05
Rating	4
ACPE Number	0107-0000-24-136-H04-P